CU20100065A7 - Combinación que comprende derivados de purina y otros compuestos y el uso de los mismos para el tratamiento de enfermedades de vías respiratorias inflamatorias y obstructivas - Google Patents
Combinación que comprende derivados de purina y otros compuestos y el uso de los mismos para el tratamiento de enfermedades de vías respiratorias inflamatorias y obstructivasInfo
- Publication number
- CU20100065A7 CU20100065A7 CU20100065A CU20100065A CU20100065A7 CU 20100065 A7 CU20100065 A7 CU 20100065A7 CU 20100065 A CU20100065 A CU 20100065A CU 20100065 A CU20100065 A CU 20100065A CU 20100065 A7 CU20100065 A7 CU 20100065A7
- Authority
- CU
- Cuba
- Prior art keywords
- inflammatory
- treatment
- antagonist
- inhibitor
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 230000000414 obstructive effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
- 150000003212 purines Chemical class 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 4
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 abstract 2
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 abstract 2
- 229940122614 Adenosine receptor agonist Drugs 0.000 abstract 1
- 101150051188 Adora2a gene Proteins 0.000 abstract 1
- 229940123169 Caspase inhibitor Drugs 0.000 abstract 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
- 229940126052 ENaC inhibitor Drugs 0.000 abstract 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
- 229940122055 Serine protease inhibitor Drugs 0.000 abstract 1
- 101710102218 Serine protease inhibitor Proteins 0.000 abstract 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 abstract 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 230000003551 muscarinic effect Effects 0.000 abstract 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 239000003001 serine protease inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un medicamento que comprende, por separado o juntos: un componente (A) el cual es un agonista de receptor de adenosina A2A como se define en la especificación; y un componente (B) el cual es uno o más compuestos seleccionados de: (i) un corticosteroide, (ii) un agonista de beta-2 adrenoceptor, (iii) un agente antimuscarínico, (iv) un antagonista de A2B, (v) una antihistamina, (Vi) un inhibidor de caspasa, (vii) un inhibidor de ENaC, (viii) un antagonista de LTB4, (ix) un antagonista de LTD4, (x) un inhibidor de serina proteasa, (xi) un inhibidor de PDE4 y (xii) un agonista de beta-2 adrenoceptor/antagonista muscarínico de acción dual, para administración simultánea, secuencial o separada en el tratamiento de una enfermedad inflamatoria u obstructiva de vías respiratorias.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07118721 | 2007-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20100065A7 true CU20100065A7 (es) | 2011-10-05 |
Family
ID=39185790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20100065A CU20100065A7 (es) | 2007-10-17 | 2010-04-14 | Combinación que comprende derivados de purina y otros compuestos y el uso de los mismos para el tratamiento de enfermedades de vías respiratorias inflamatorias y obstructivas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20090181934A1 (es) |
| EP (1) | EP2211865A2 (es) |
| JP (1) | JP2011500630A (es) |
| KR (1) | KR20100075925A (es) |
| CN (1) | CN101827596A (es) |
| AR (1) | AR068879A1 (es) |
| AU (1) | AU2008313788A1 (es) |
| BR (1) | BRPI0818005A2 (es) |
| CA (1) | CA2702942A1 (es) |
| CL (1) | CL2008003057A1 (es) |
| CR (1) | CR11341A (es) |
| CU (1) | CU20100065A7 (es) |
| EA (1) | EA201000617A1 (es) |
| IL (1) | IL204723A0 (es) |
| MA (1) | MA31796B1 (es) |
| MX (1) | MX2010004252A (es) |
| PE (1) | PE20091392A1 (es) |
| TN (1) | TN2010000168A1 (es) |
| TW (1) | TW200927129A (es) |
| WO (1) | WO2009050198A2 (es) |
| ZA (1) | ZA201002336B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| PT2322525E (pt) * | 2006-04-21 | 2013-12-26 | Novartis Ag | Derivados de purina para utilização como agonistas do recetor de adenosina a2a |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| CN101553459A (zh) * | 2006-11-10 | 2009-10-07 | 诺瓦提斯公司 | 环戊烯二醇单乙酸酯衍生物 |
| BRPI0818578A2 (pt) * | 2007-10-17 | 2015-07-21 | Novartis Ag | Derivados de purina como ligantes receptores de adenosina a1 |
| KR20140146217A (ko) | 2012-04-20 | 2014-12-24 | 유씨비 파마, 에스.에이. | 파킨슨병을 치료하는 방법 |
| MX2021008094A (es) | 2019-01-11 | 2021-09-21 | Omeros Corp | Metodos y composiciones para el tratamiento del cancer. |
| WO2026006723A1 (en) * | 2024-06-27 | 2026-01-02 | Anand Rene | Reagents and methods for treating headache and migraine pain and co-morbidities thereof |
| WO2026064126A1 (en) | 2024-09-19 | 2026-03-26 | University Of Rochester | Use of gadd34 inhibitors such as sephin1 for the treatment of fibrotic airways disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| PT2322525E (pt) * | 2006-04-21 | 2013-12-26 | Novartis Ag | Derivados de purina para utilização como agonistas do recetor de adenosina a2a |
-
2008
- 2008-10-08 US US12/247,764 patent/US20090181934A1/en not_active Abandoned
- 2008-10-15 PE PE2008001774A patent/PE20091392A1/es not_active Application Discontinuation
- 2008-10-15 WO PCT/EP2008/063869 patent/WO2009050198A2/en not_active Ceased
- 2008-10-15 AU AU2008313788A patent/AU2008313788A1/en not_active Abandoned
- 2008-10-15 EP EP08838649A patent/EP2211865A2/en not_active Withdrawn
- 2008-10-15 MX MX2010004252A patent/MX2010004252A/es not_active Application Discontinuation
- 2008-10-15 JP JP2010529369A patent/JP2011500630A/ja active Pending
- 2008-10-15 KR KR1020107008300A patent/KR20100075925A/ko not_active Withdrawn
- 2008-10-15 EA EA201000617A patent/EA201000617A1/ru unknown
- 2008-10-15 CA CA2702942A patent/CA2702942A1/en not_active Abandoned
- 2008-10-15 AR ARP080104494A patent/AR068879A1/es not_active Application Discontinuation
- 2008-10-15 CN CN200880112188A patent/CN101827596A/zh active Pending
- 2008-10-15 BR BRPI0818005 patent/BRPI0818005A2/pt not_active IP Right Cessation
- 2008-10-16 TW TW097139728A patent/TW200927129A/zh unknown
- 2008-10-16 CL CL2008003057A patent/CL2008003057A1/es unknown
-
2010
- 2010-03-25 IL IL204723A patent/IL204723A0/en unknown
- 2010-03-26 CR CR11341A patent/CR11341A/es not_active Application Discontinuation
- 2010-04-01 ZA ZA2010/02336A patent/ZA201002336B/en unknown
- 2010-04-14 CU CU20100065A patent/CU20100065A7/es unknown
- 2010-04-16 TN TN2010000168A patent/TN2010000168A1/fr unknown
- 2010-04-30 MA MA32802A patent/MA31796B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008313788A1 (en) | 2009-04-23 |
| JP2011500630A (ja) | 2011-01-06 |
| WO2009050198A2 (en) | 2009-04-23 |
| IL204723A0 (en) | 2010-11-30 |
| KR20100075925A (ko) | 2010-07-05 |
| CL2008003057A1 (es) | 2009-06-26 |
| TW200927129A (en) | 2009-07-01 |
| AR068879A1 (es) | 2009-12-09 |
| ZA201002336B (en) | 2011-04-28 |
| BRPI0818005A2 (pt) | 2015-04-14 |
| EP2211865A2 (en) | 2010-08-04 |
| US20090181934A1 (en) | 2009-07-16 |
| TN2010000168A1 (en) | 2011-11-11 |
| PE20091392A1 (es) | 2009-10-14 |
| EA201000617A1 (ru) | 2010-10-29 |
| MA31796B1 (fr) | 2010-10-01 |
| MX2010004252A (es) | 2010-04-30 |
| WO2009050198A3 (en) | 2009-09-11 |
| CR11341A (es) | 2010-05-06 |
| CN101827596A (zh) | 2010-09-08 |
| CA2702942A1 (en) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20100065A7 (es) | Combinación que comprende derivados de purina y otros compuestos y el uso de los mismos para el tratamiento de enfermedades de vías respiratorias inflamatorias y obstructivas | |
| PE20081361A1 (es) | Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
| ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| ECSP099387A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis | |
| MX347525B (es) | Inhibidores de tirosina cinasa de bruton. | |
| WO2009017838A3 (en) | Combinations of jak-2 inhibitors and other agents | |
| EA201000211A1 (ru) | Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения | |
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| BR112014012727A2 (pt) | cloridreto derivado de purinona | |
| SG158870A1 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
| CL2008002207A1 (es) | Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04). | |
| PE20120476A1 (es) | Composiciones farmaceuticas estabilizadas que comprenden fesoterodina | |
| PA8849701A1 (es) | Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de anglotensina ii y/o un diuretico | |
| WO2007092936A3 (en) | Method to treat gastric lesions | |
| AR051968A1 (es) | Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central | |
| GT200900089A (es) | Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine | |
| MX2021005839A (es) | Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso. | |
| BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação | |
| DK1959939T3 (da) | Anvendelse af a3-adenosinreceptoragonist i behandlingen af osteoarthritis | |
| AR060284A1 (es) | Terapia de combinacion de (2r,z)-2-amino-2-ciclohexil-n-(5-(1-metil-1h- pirazol- 4-il)-1- oxo- 2,6 dihidro-1h- [1,2] diazepino [4,5,6-cd] indol-8-il) acetamida | |
| MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
| UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| UY30424A1 (es) | Derivados de quinolina, su preparacion, su uso y medicamentos que comprenden los mismos. |